5 research outputs found
Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and
treatment-related acutemyeloid leukemia (tAML) after chemotherapy or radiation therapy
for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal
encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes
in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the
cases of four consecutive patients with AML-MRC or tAML who received CPX-351
as outpatient induction therapy immediately followed by allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in
complete remission and one in partial remission) and two patients received allo-HSCT
in aplasia (one at 11 days and one at 52 days after the start of induction therapy with
CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are
alive and two are in remission. Further studies will help define and expand the role of
CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to
undergo allo-HSCT
Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and
treatment-related acutemyeloid leukemia (tAML) after chemotherapy or radiation therapy
for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal
encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes
in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the
cases of four consecutive patients with AML-MRC or tAML who received CPX-351
as outpatient induction therapy immediately followed by allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in
complete remission and one in partial remission) and two patients received allo-HSCT
in aplasia (one at 11 days and one at 52 days after the start of induction therapy with
CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are
alive and two are in remission. Further studies will help define and expand the role of
CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to
undergo allo-HSCT
Analysis of stem cell collections in adult patients with Ewing sarcoma
Background: Ewing sarcoma is one of the most frequent soft-tissue tumors in
pediatric patients. The current treatment protocols recommend stem cell apheresis (SCA) after completion of the second course of induction therapy with
vincristine, ifosfamide, doxorubicine, and etoposide (VIDE). The feasibility of
SCA and graft compositions in adult patients with Ewing sarcoma have not
been previously analyzed.
Methods and Materials: The authors analyzed 29 stem cell collections of
19 adult patients (9 male, 10 female) at a median age of 27 (range 19–53) years
mobilized after VIDE (n = 17), cyclophosphamide/topotecan (n = 1) or
vincristine, dactinomycin and ifosfamide (n = 1) chemotherapy. All patients
were mobilized with filgrastim 5 μg/kg twice daily from day +7 of chemotherapy. The collections were performed if CD34+ cell count in peripheral blood
was >10/μL. The target yields were ≥4106 CD34+ cells/kg body weight.
Results: Median CD34+ cells/μL in peripheral blood before SCA were 45.8
(range 6.7–614.4)/μL. The median cumulative yields were 10.6 (range 1.5–38.8)
CD34+ cells/kg body weight and ≥2106 in all but two patients (89%). CD34,
CD3, and CD56 yields in collections after the third VIDE and after later
courses did not differ. Four patients underwent high-dose therapy with
autologous transplantation, and all were engrafted.
Discussion: Stem cell mobilization is feasible in most Ewing sarcoma patients.
Additionally, the present study's data suggest that it is safe to postpone stem
cell collection to a later VIDE chemotherapy cycle if medically indicate
Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and
treatment-related acutemyeloid leukemia (tAML) after chemotherapy or radiation therapy
for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal
encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes
in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the
cases of four consecutive patients with AML-MRC or tAML who received CPX-351
as outpatient induction therapy immediately followed by allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in
complete remission and one in partial remission) and two patients received allo-HSCT
in aplasia (one at 11 days and one at 52 days after the start of induction therapy with
CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are
alive and two are in remission. Further studies will help define and expand the role of
CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to
undergo allo-HSCT
Analysis of stem cell collections in adult patients with Ewing sarcoma
Background: Ewing sarcoma is one of the most frequent soft-tissue tumors in
pediatric patients. The current treatment protocols recommend stem cell apheresis (SCA) after completion of the second course of induction therapy with
vincristine, ifosfamide, doxorubicine, and etoposide (VIDE). The feasibility of
SCA and graft compositions in adult patients with Ewing sarcoma have not
been previously analyzed.
Methods and Materials: The authors analyzed 29 stem cell collections of
19 adult patients (9 male, 10 female) at a median age of 27 (range 19–53) years
mobilized after VIDE (n = 17), cyclophosphamide/topotecan (n = 1) or
vincristine, dactinomycin and ifosfamide (n = 1) chemotherapy. All patients
were mobilized with filgrastim 5 μg/kg twice daily from day +7 of chemotherapy. The collections were performed if CD34+ cell count in peripheral blood
was >10/μL. The target yields were ≥4106 CD34+ cells/kg body weight.
Results: Median CD34+ cells/μL in peripheral blood before SCA were 45.8
(range 6.7–614.4)/μL. The median cumulative yields were 10.6 (range 1.5–38.8)
CD34+ cells/kg body weight and ≥2106 in all but two patients (89%). CD34,
CD3, and CD56 yields in collections after the third VIDE and after later
courses did not differ. Four patients underwent high-dose therapy with
autologous transplantation, and all were engrafted.
Discussion: Stem cell mobilization is feasible in most Ewing sarcoma patients.
Additionally, the present study's data suggest that it is safe to postpone stem
cell collection to a later VIDE chemotherapy cycle if medically indicate